Disease Overview
Glioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells that support nerve cells. It is characterized by rapid growth and its high potential to invade surrounding tissue. GBM is the most lethal type of brain tumor, with fewer than 10% of patients surviving more than five years after diagnosis. It is considered to be incurable, with nearly 100% of patients experiencing disease relapse after initial treatment.
Market Snapshot
Glioblastoma (GBM) is the most common and most aggressive type of malignant primary brain tumor. It is a malignant glioma that develops from astrocytes, which are star-shaped glial cells that support nerve cells. It is characterized by rapid growth and its high potential to invade surrounding tissue. GBM is the most lethal type of brain tumor, with fewer than 10% of patients surviving more than five years after diagnosis. It is considered to be incurable, with nearly 100% of patients experiencing disease relapse after initial treatment.
Market Snapshot
- Approval of Opdivo is expected to make the largest contribution to market growth over the forecast period.
- Temozolomide remains the backbone of therapy across all treatment settings.
- Incident cases of glioblastoma are forecast to increase by 23% during 2017–37.
- Temodar’s future lies in drug combinations, while Avastin will be impacted by biosimilars and pipeline therapies.
- Innovative immunotherapies and gene therapies look to serve critically unmet needs in the glioblastoma market.
Table of Contents
FORECAST: GLIOBLASTOMA (Published on 30 March 2017)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Avastin (Bevacizumab)
Dcvax-L
Ict-107
Opdivo (Nivolumab)
Temodar (Temozolomide)
Toca 511/Fc
Vb-111
Primary Research Methodology
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Avastin (Bevacizumab)
Dcvax-L
Ict-107
Opdivo (Nivolumab)
Temodar (Temozolomide)
Toca 511/Fc
Vb-111
Primary Research Methodology
TREATMENT: GLIOBLASTOMA (Published on 12 January 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
EPIDEMIOLOGY: GLIOBLASTOMA (Published on 14 June 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
MARKETED DRUGS: GLIOBLASTOMA (Published on 30 March 2017)
Overview
Executive Summary
Product Overview
Product Profile: Avastin
Product Profile: Temodar
Executive Summary
Product Overview
Product Profile: Avastin
Product Profile: Temodar
PIPELINE: GLIOBLASTOMA (Published on 30 March 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Recently Discontinued Drugs
Latest Analyst Opinion
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Dcvax-L
Product Profile (Late Stage): Ict-107
Product Profile (Late Stage): Opdivo
Product Profile (Late Stage): Toca 511/Fc
Product Profile (Late Stage): Vb-111
Executive Summary
Clinical Pipeline Overview
Target Product Profile
Clinical Trial Design
Recently Discontinued Drugs
Latest Analyst Opinion
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Dcvax-L
Product Profile (Late Stage): Ict-107
Product Profile (Late Stage): Opdivo
Product Profile (Late Stage): Toca 511/Fc
Product Profile (Late Stage): Vb-111
LIST OF FIGURES
Figure 1: Glioblastoma market value across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Glioblastoma sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 3: Sales of dendritic cell vaccines in glioblastoma across the US and five major EU markets, by product, 2016–25
Figure 4: Sales of gene therapies in glioblastoma, by product, 2016–25
Figure 5: Glioblastoma patient numbers and sales for Avastin and Temodar across the US, Japan, and five major EU markets, 2016–25
Figure 6: Glioblastoma sales in the US, by class, 2016–25
Figure 7: Glioblastoma sales in Japan, by class, 2016–25
Figure 8: Glioblastoma sales across the five major EU markets, by class, 2016–25
Figure 9: Methodology flow for The authors glioblastoma forecast
Figure 10: Price sources and calculations, by country
Figure 11: Avastin sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: DCVax-L sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: ICT-107 sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Opdivo sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Temodar sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Toca 511/FC sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 17: VB-111 sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 18: Proportion of glioblastoma patients at each stage of disease, by country
Figure 19: Proportion of glioblastoma patients presenting with primary versus secondary disease at diagnosis, by country
Figure 20: Top five treatment types for newly diagnosed glioblastoma patients, by country
Figure 21: Proportion of newly diagnosed glioblastoma patients treated with surgery who receive maximal safe resection versus subtotal resection, by country
Figure 22: Proportion of newly diagnosed patients receiving a carmustine wafer alongside maximal safe resection versus subtotal resection, by country
Figure 23: Top five concurrent pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have previously received surgery, by country
Figure 24: Top five concurrent pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have not previously received surgery, by country
Figure 25: Top five adjuvant pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have previously received surgery, by country
Figure 26: Top five adjuvant pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have not previously received surgery, by country
Figure 27: Top five pharmacological therapies prescribed for newly diagnosed glioblastoma patients receiving pharmacological therapy alone, by country
Figure 28: Average percentage of newly diagnosed glioblastoma patients who go on to develop recurrent disease, and average time to recurrence, by treatment type
Figure 29: Proportion of local recurrent glioblastoma patients with resectable versus unresectable disease, by country
Figure 30: Proportion of local resectable recurrent versus local unresectable recurrent glioblastoma patients progressing to diffuse/multiple disease, by country
Figure 31: Proportion of local resectable recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 32: Proportion of local unresectable recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 33: Proportion of diffuse/multiple recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 34: Top five first-line pharmacological regimens prescribed for the treatment of local resectable recurrent glioblastoma patients, by country
Figure 35: Top five first-line pharmacological regimens prescribed for the treatment of local unresectable recurrent glioblastoma patients, by country
Figure 36: Top five first-line pharmacological regimens prescribed for the treatment of diffuse/multiple recurrent glioblastoma patients, by country
Figure 37: Top five second-line pharmacological regimens prescribed for the treatment of local resectable recurrent glioblastoma patients, by country
Figure 38: Top five second-line pharmacological regimens prescribed for the treatment of local unresectable recurrent lioblastoma patients, by country
Figure 39: Top five second-line pharmacological regimens prescribed for the treatment of diffuse/multiple recurrent glioblastoma patients, by country
Figure 40: Trends in incident cases of glioblastoma in the US, Japan, and five major EU markets, by country, 2017–37
Figure 41: Avastin for glioblastoma – SWOT analysis
Figure 42: The authors drug assessment summary of Avastin in glioblastoma
Figure 43: The authors drug assessment summary of Avastin in glioblastoma
Figure 44: Temodar for glioblastoma – SWOT analysis
Figure 45: The authors drug assessment summary of Temodar in glioblastoma
Figure 46: The authors drug assessment summary of Temodar in glioblastoma
Figure 47: DCVax-L for glioblastoma – SWOT analysis
Figure 48: The authors drug assessment summary for DCVax-L in glioblastoma
Figure 49: The authors drug assessment summary for DCVax-L in glioblastoma multiforme
Figure 50: ICT-107 for glioblastoma – SWOT analysis
Figure 51: The authors drug assessment summary for ICT-107 in glioblastoma multiforme
Figure 52: The authors drug assessment summary for ICT-107 in glioblastoma multiforme
Figure 53: Opdivo for glioblastoma – SWOT analysis
Figure 54: The authors drug assessment summary for Opdivo in glioblastoma
Figure 55: The authors drug assessment summary for Opdivo in glioblastoma
Figure 56: Toca 511/FC for glioblastoma – SWOT analysis
Figure 57: The authors drug assessment summary for Toca 511/FC in glioblastoma
Figure 58: The authors drug assessment summary for Toca 511/FC in glioblastoma
Figure 59: VB-111 for glioblastoma – SWOT analysis
Figure 60: The authors drug assessment summary for VB-111 in glioblastoma
Figure 61: The authors drug assessment summary for VB-111 in glioblastoma
Figure 2: Glioblastoma sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 3: Sales of dendritic cell vaccines in glioblastoma across the US and five major EU markets, by product, 2016–25
Figure 4: Sales of gene therapies in glioblastoma, by product, 2016–25
Figure 5: Glioblastoma patient numbers and sales for Avastin and Temodar across the US, Japan, and five major EU markets, 2016–25
Figure 6: Glioblastoma sales in the US, by class, 2016–25
Figure 7: Glioblastoma sales in Japan, by class, 2016–25
Figure 8: Glioblastoma sales across the five major EU markets, by class, 2016–25
Figure 9: Methodology flow for The authors glioblastoma forecast
Figure 10: Price sources and calculations, by country
Figure 11: Avastin sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: DCVax-L sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: ICT-107 sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Opdivo sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Temodar sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Toca 511/FC sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 17: VB-111 sales for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Figure 18: Proportion of glioblastoma patients at each stage of disease, by country
Figure 19: Proportion of glioblastoma patients presenting with primary versus secondary disease at diagnosis, by country
Figure 20: Top five treatment types for newly diagnosed glioblastoma patients, by country
Figure 21: Proportion of newly diagnosed glioblastoma patients treated with surgery who receive maximal safe resection versus subtotal resection, by country
Figure 22: Proportion of newly diagnosed patients receiving a carmustine wafer alongside maximal safe resection versus subtotal resection, by country
Figure 23: Top five concurrent pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have previously received surgery, by country
Figure 24: Top five concurrent pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have not previously received surgery, by country
Figure 25: Top five adjuvant pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have previously received surgery, by country
Figure 26: Top five adjuvant pharmacological therapies prescribed for newly diagnosed glioblastoma patients who have not previously received surgery, by country
Figure 27: Top five pharmacological therapies prescribed for newly diagnosed glioblastoma patients receiving pharmacological therapy alone, by country
Figure 28: Average percentage of newly diagnosed glioblastoma patients who go on to develop recurrent disease, and average time to recurrence, by treatment type
Figure 29: Proportion of local recurrent glioblastoma patients with resectable versus unresectable disease, by country
Figure 30: Proportion of local resectable recurrent versus local unresectable recurrent glioblastoma patients progressing to diffuse/multiple disease, by country
Figure 31: Proportion of local resectable recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 32: Proportion of local unresectable recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 33: Proportion of diffuse/multiple recurrent glioblastoma patients receiving each treatment type at first line, by country
Figure 34: Top five first-line pharmacological regimens prescribed for the treatment of local resectable recurrent glioblastoma patients, by country
Figure 35: Top five first-line pharmacological regimens prescribed for the treatment of local unresectable recurrent glioblastoma patients, by country
Figure 36: Top five first-line pharmacological regimens prescribed for the treatment of diffuse/multiple recurrent glioblastoma patients, by country
Figure 37: Top five second-line pharmacological regimens prescribed for the treatment of local resectable recurrent glioblastoma patients, by country
Figure 38: Top five second-line pharmacological regimens prescribed for the treatment of local unresectable recurrent lioblastoma patients, by country
Figure 39: Top five second-line pharmacological regimens prescribed for the treatment of diffuse/multiple recurrent glioblastoma patients, by country
Figure 40: Trends in incident cases of glioblastoma in the US, Japan, and five major EU markets, by country, 2017–37
Figure 41: Avastin for glioblastoma – SWOT analysis
Figure 42: The authors drug assessment summary of Avastin in glioblastoma
Figure 43: The authors drug assessment summary of Avastin in glioblastoma
Figure 44: Temodar for glioblastoma – SWOT analysis
Figure 45: The authors drug assessment summary of Temodar in glioblastoma
Figure 46: The authors drug assessment summary of Temodar in glioblastoma
Figure 47: DCVax-L for glioblastoma – SWOT analysis
Figure 48: The authors drug assessment summary for DCVax-L in glioblastoma
Figure 49: The authors drug assessment summary for DCVax-L in glioblastoma multiforme
Figure 50: ICT-107 for glioblastoma – SWOT analysis
Figure 51: The authors drug assessment summary for ICT-107 in glioblastoma multiforme
Figure 52: The authors drug assessment summary for ICT-107 in glioblastoma multiforme
Figure 53: Opdivo for glioblastoma – SWOT analysis
Figure 54: The authors drug assessment summary for Opdivo in glioblastoma
Figure 55: The authors drug assessment summary for Opdivo in glioblastoma
Figure 56: Toca 511/FC for glioblastoma – SWOT analysis
Figure 57: The authors drug assessment summary for Toca 511/FC in glioblastoma
Figure 58: The authors drug assessment summary for Toca 511/FC in glioblastoma
Figure 59: VB-111 for glioblastoma – SWOT analysis
Figure 60: The authors drug assessment summary for VB-111 in glioblastoma
Figure 61: The authors drug assessment summary for VB-111 in glioblastoma
LIST OF TABLES
Table 1: Glioblastoma market value across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Glioblastoma sales in the US, by brand and class ($m), 2016–25
Table 3: Glioblastoma sales in Japan, by brand and class ($m), 2016–25
Table 4: Glioblastoma sales in the five major EU markets, by brand and class ($m), 2016–25
Table 5: Summary of drug classes and molecules included in the glioblastoma patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in glioblastoma in the US, Japan, and five major EU markets, by region
Table 8: Forecast launch dates of key late-stage pipeline products and generic/biosimilar drugs in glioblastoma in the US, Japan, and five major EU markets, by region
Table 9: Avastin sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Avastin patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 11: DCVax-L sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: DCVax-L patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 13: ICT-107 sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: ICT-107 patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 15: Opdivo sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Opdivo patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 17: Temodar sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Temodar patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 19: Toca 511/FC sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 20: Toca 511/FC patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 21: VB-111 sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: VB-111 patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 23: Medical oncologists, neuro-oncologists, neurosurgeons and neurologists surveyed for the glioblastoma primary research study, 2016
Table 24: Medical oncologists, neuro-oncologists, neurosurgeons, and neurologists surveyed for the glioblastoma primary research study, 2016
Table 25: Genetic syndromes and associated gene mutations linked to increased risk of developing glioblastoma
Table 26: Leading brands available for glioblastoma across the US, Japan, and five major EU markets
Table 27: Common chemotherapies used for the treatment of glioblastoma
Table 28: Cancer registry databases used as a source of glioblastoma incidence data, by country
Table 29: Forecasting methodology for glioblastoma incidence, by country, age group, and gender
Table 30: Sources of survival data used to estimate glioblastoma prevalence
Table 31: Incident cases of glioblastoma in the US, Japan, and five major EU markets, by country, 2017–37
Table 32: Key marketed drugs for glioblastoma
Table 33: Avastin drug profile
Table 34: Avastin pivotal trial data in glioblastoma
Table 35: Avastin late-phase trial data in glioblastoma
Table 36: Avastin ongoing late-phase clinical trials in glioblastoma
Table 37: Temodar drug profile
Table 38: Temodar pivotal trial data in glioblastoma
Table 39: Temodar late-phase trial data in glioblastoma
Table 40: Phase III pipeline products in development for glioblastoma
Table 41: Temodar drug profile
Table 42: Temodar pivotal trial data in glioblastoma
Table 43: Typical Phase III clinical trial design in newly diagnosed glioblastoma
Table 44: Typical Phase III clinical trial design in recurrent glioblastoma
Table 45: Late-stage compounds that were recently discontinued for glioblastoma
Table 46: Rintega drug profile
Table 47: Rintega late-phase trial in glioblastoma
Table 48: Rintega late-phase trial data in glioblastoma
Table 49: DCVax-L drug profile
Table 50: DCVax-L Phase III trials in glioblastoma
Table 51: DCVax-L Phase III data in glioblastoma
Table 52: ICT-107 drug profile
Table 53: ICT-107 Phase III trials in glioblastoma
Table 54: ICT-107 early-phase data in glioblastoma
Table 55: Opdivo drug profile
Table 56: Opdivo Phase III data in glioblastoma
Table 57: Opdivo Phase III trials in glioblastoma
Table 58: Toca 511/FC drug profile
Table 59: Toca 511/FC Phase III trials in glioblastoma
Table 60: Toca 511/FC early-phase data in glioblastoma
Table 61: VB-111 drug profile
Table 62: VB-111 Phase III trials in glioblastoma
Table 63: VB-111 Phase II data in glioblastoma
Table 2: Glioblastoma sales in the US, by brand and class ($m), 2016–25
Table 3: Glioblastoma sales in Japan, by brand and class ($m), 2016–25
Table 4: Glioblastoma sales in the five major EU markets, by brand and class ($m), 2016–25
Table 5: Summary of drug classes and molecules included in the glioblastoma patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in glioblastoma in the US, Japan, and five major EU markets, by region
Table 8: Forecast launch dates of key late-stage pipeline products and generic/biosimilar drugs in glioblastoma in the US, Japan, and five major EU markets, by region
Table 9: Avastin sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Avastin patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 11: DCVax-L sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: DCVax-L patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 13: ICT-107 sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: ICT-107 patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 15: Opdivo sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Opdivo patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 17: Temodar sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Temodar patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 19: Toca 511/FC sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 20: Toca 511/FC patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 21: VB-111 sales for glioblastoma across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: VB-111 patient numbers for glioblastoma across the US, Japan, and five major EU markets, by country, 2016–25
Table 23: Medical oncologists, neuro-oncologists, neurosurgeons and neurologists surveyed for the glioblastoma primary research study, 2016
Table 24: Medical oncologists, neuro-oncologists, neurosurgeons, and neurologists surveyed for the glioblastoma primary research study, 2016
Table 25: Genetic syndromes and associated gene mutations linked to increased risk of developing glioblastoma
Table 26: Leading brands available for glioblastoma across the US, Japan, and five major EU markets
Table 27: Common chemotherapies used for the treatment of glioblastoma
Table 28: Cancer registry databases used as a source of glioblastoma incidence data, by country
Table 29: Forecasting methodology for glioblastoma incidence, by country, age group, and gender
Table 30: Sources of survival data used to estimate glioblastoma prevalence
Table 31: Incident cases of glioblastoma in the US, Japan, and five major EU markets, by country, 2017–37
Table 32: Key marketed drugs for glioblastoma
Table 33: Avastin drug profile
Table 34: Avastin pivotal trial data in glioblastoma
Table 35: Avastin late-phase trial data in glioblastoma
Table 36: Avastin ongoing late-phase clinical trials in glioblastoma
Table 37: Temodar drug profile
Table 38: Temodar pivotal trial data in glioblastoma
Table 39: Temodar late-phase trial data in glioblastoma
Table 40: Phase III pipeline products in development for glioblastoma
Table 41: Temodar drug profile
Table 42: Temodar pivotal trial data in glioblastoma
Table 43: Typical Phase III clinical trial design in newly diagnosed glioblastoma
Table 44: Typical Phase III clinical trial design in recurrent glioblastoma
Table 45: Late-stage compounds that were recently discontinued for glioblastoma
Table 46: Rintega drug profile
Table 47: Rintega late-phase trial in glioblastoma
Table 48: Rintega late-phase trial data in glioblastoma
Table 49: DCVax-L drug profile
Table 50: DCVax-L Phase III trials in glioblastoma
Table 51: DCVax-L Phase III data in glioblastoma
Table 52: ICT-107 drug profile
Table 53: ICT-107 Phase III trials in glioblastoma
Table 54: ICT-107 early-phase data in glioblastoma
Table 55: Opdivo drug profile
Table 56: Opdivo Phase III data in glioblastoma
Table 57: Opdivo Phase III trials in glioblastoma
Table 58: Toca 511/FC drug profile
Table 59: Toca 511/FC Phase III trials in glioblastoma
Table 60: Toca 511/FC early-phase data in glioblastoma
Table 61: VB-111 drug profile
Table 62: VB-111 Phase III trials in glioblastoma
Table 63: VB-111 Phase II data in glioblastoma
